Notably, pharmacological inhibition of STAT3 has been proved to sabotage bladder cancer progression in murine model, therefore highlighting STAT3 as a promising target for the development of bladder cancer therapeutics [22]. This evidence concerns the gene STAT3 and urinary bladder cancer.